1. Analysis of Cell-Free DNA to Assess Risk of Tumoremia Following Endoscopic Ultrasound Fine-Needle Aspiration of Pancreatic Adenocarcinomas 
Michael J. Levy, Benjamin R. Kipp, Dragana Milosevic, Amber R. Schneider, Jesse S. Voss, Rajeswari Avula, Sarah E. Kerr, Michael R. Henry, Edward Highsmith, Minetta C. Liu, Ferga C. Gleeson 
Clinical Gastroenterology and Hepatology 
Volume 16, Issue 10, Pages e1 (October 2018)
DOI: /j.cgh
Copyright © 2018 AGA Institute Terms and Conditions

2. Figure 1
Total cell-free DNA (cfDNA) concentrations for pre- and post-fine needle aspiration (FNA) samples obtained from peripheral blood.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions

3. Figure 2
Total cell-free DNA (cfDNA) concentrations for pre- and post-fine needle aspiration (FNA) samples obtained portal vein (left), and hepatic vein (right) blood.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions

4. Figure 3
Digital droplet polymerase chain reaction cell-free DNA (cfDNA) KRAS 12/13 analysis. Distribution of droplets is visualized using a heat map. Droplet threshold are shown as pink lines. Signal detected in the channel represents DNA positive for a KRAS 12/13 mutation. Signal detected in HEX channel represents DNA positive for KRAS wild-type (WT) amplification in which cfDNA mutants were nondetectable. (A) Sample positive for a mutation in codon 12/13 in the KRAS gene. Distribution of negative droplets (NEG), droplets positive for mutation in KRAS codon 12/13 (KRAS 12/13+), and droplets positive for KRAS WT. (B) Sample negative for mutation in codons 12/13 of the KRAS gene, but amplifies KRAS WT. (C) Sample without DNA showing no positive droplets in neither the FAM channel nor the HEX channel.
Clinical Gastroenterology and Hepatology  , e1DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions